Plant Derived Bioactive Compounds, Their Anti-Cancer Effects as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview

For decades, cancer has been a major public health concern worldwide owing to its high mortality rate. Many therapeutic strategies have come up in the scientific world, but it\u27s pitiful to know that synthetic chemotherapeutic agents either cause adverse effects or cancer cells develop resistance to these agents. Plant-derived chemotherapeutic agents present a wide range of therapeutics and most are yet to be discovered. In the current review, we have discussed the tumoricidal properties of Mucuna pruriens (seed), Withania coagulans (berry), Anacyclus pyrethrum (rhizome), Arachis hypogea (leaf), Rhizaoma polygoni (root) and Terminalia chebula (fruit). We have also tried to summarize the latest research in cancer chemoprevention and treatment using the bioactive components from these natural plants. Pharmaceutical developmental challenges and opportunities in bringing the phytochemicals into the market are also explored. The authors wish to expand this research area not only for their scientific soundness, but also for their potential-yet-affordable druggability

Not Available

Not AvailableThe spike (S) glycoprotein and nucleocapsid (N) proteins are the crucial pathogenic proteins of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus during its interaction with the host. Even FDA-approved drugs like dexamethasone and grazoprevir are not able to curb the viral progression inside the host and are reported with adverse effects on body metabolism. In this context, we aim to report corilagin a novel, potential dual inhibitor of S and N proteins from Terminalia chebula. The bioactive compounds of T. chebula were subjected to a series of computational investigations including molecular docking simulations, molecular dynamics (MD) simulations, binding free energy calculations, and PASS pharmacological analysis. The results obtained from these studies revealed that corilagin was highly interactive with the S (-8.9 kcal/mol) and N (-9.2 kcal/mol) proteins, thereby showing dual inhibition activity. It was also found to be stable enough to induce biological activity inside the inhibitor binding pocket of the target enzymes throughout the dynamics simulation run for 100 ns. This is also confirmed by the changes in the protein conformations, evaluated using free energy landscapes. Outcomes from this investigation identify corilagin as the lead potential dual inhibitor of S and N proteins of SARS-CoV-2, which could be taken for biological studies in near future.Communicated by Ramaswamy H. Sarma.Not Availabl